NEUPHORIA THERAPEUTICS INC (NEUP) Fundamental Analysis & Valuation

NASDAQ:NEUP • US64136E1029

Current stock price

4.1 USD
-0.1 (-2.38%)
Last:

This NEUP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NEUP Profitability Analysis

1.1 Basic Checks

  • NEUP had negative earnings in the past year.
  • In the past year NEUP has reported a negative cash flow from operations.
  • In the past 5 years NEUP always reported negative net income.
  • NEUP had negative operating cash flow in 4 of the past 5 years.
NEUP Yearly Net Income VS EBIT VS OCF VS FCFNEUP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M -25M

1.2 Ratios

  • NEUP's Return On Assets of -15.48% is fine compared to the rest of the industry. NEUP outperforms 78.61% of its industry peers.
  • The Return On Equity of NEUP (-19.07%) is better than 82.27% of its industry peers.
Industry RankSector Rank
ROA -15.48%
ROE -19.07%
ROIC N/A
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUP Yearly ROA, ROE, ROICNEUP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NEUP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUP Yearly Profit, Operating, Gross MarginsNEUP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NEUP Health Analysis

2.1 Basic Checks

  • NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEUP has been reduced compared to 1 year ago.
  • Compared to 5 years ago, NEUP has less shares outstanding
  • NEUP has a better debt/assets ratio than last year.
NEUP Yearly Shares OutstandingNEUP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NEUP Yearly Total Debt VS Total AssetsNEUP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -4.28, we must say that NEUP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of NEUP (-4.28) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.00 indicates that NEUP is not too dependend on debt financing.
  • NEUP has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.28
ROIC/WACCN/A
WACC9.4%
NEUP Yearly LT Debt VS Equity VS FCFNEUP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

2.3 Liquidity

  • A Current Ratio of 9.04 indicates that NEUP has no problem at all paying its short term obligations.
  • NEUP's Current ratio of 9.04 is fine compared to the rest of the industry. NEUP outperforms 77.26% of its industry peers.
  • NEUP has a Quick Ratio of 9.04. This indicates that NEUP is financially healthy and has no problem in meeting its short term obligations.
  • NEUP's Quick ratio of 9.04 is fine compared to the rest of the industry. NEUP outperforms 77.26% of its industry peers.
Industry RankSector Rank
Current Ratio 9.04
Quick Ratio 9.04
NEUP Yearly Current Assets VS Current LiabilitesNEUP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NEUP Growth Analysis

3.1 Past

  • The earnings per share for NEUP have decreased strongly by -130.00% in the last year.
  • NEUP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 247.24% yearly.
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.41%
Revenue 1Y (TTM)N/A
Revenue growth 3Y334.33%
Revenue growth 5Y247.24%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, NEUP will show a very negative growth in Earnings Per Share. The EPS will decrease by -104.33% on average per year.
  • The Revenue is expected to grow by 42.50% on average over the next years. This is a very strong growth
EPS Next Y-1180.52%
EPS Next 2Y-267.84%
EPS Next 3Y-104.33%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.5%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NEUP Yearly Revenue VS EstimatesNEUP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2030 2031 2032 2033 0 100M 200M 300M
NEUP Yearly EPS VS EstimatesNEUP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. NEUP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NEUP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NEUP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUP Price Earnings VS Forward Price EarningsNEUP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUP Per share dataNEUP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A cheap valuation may be justified as NEUP's earnings are expected to decrease with -104.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-267.84%
EPS Next 3Y-104.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NEUP Dividend Analysis

5.1 Amount

  • No dividends for NEUP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUP Fundamentals: All Metrics, Ratios and Statistics

NEUPHORIA THERAPEUTICS INC

NASDAQ:NEUP (3/27/2026, 8:00:01 PM)

4.1

-0.1 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-18
Inst Owners29.79%
Inst Owner Change665.76%
Ins Owners3.41%
Ins Owner ChangeN/A
Market Cap22.10M
Revenue(TTM)15.00M
Net Income(TTM)-5.66M
Analysts80
Price Target9.96 (142.93%)
Short Float %0.29%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-88.74%
Min EPS beat(2)-225.89%
Max EPS beat(2)48.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-32.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.5%
EPS NY rev (1m)0%
EPS NY rev (3m)14.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-4.43
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS2.78
BVpS5.51
TBVpS3.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.48%
ROE -19.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.04
Quick Ratio 9.04
Altman-Z -4.28
F-Score6
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.41%
EPS Next Y-1180.52%
EPS Next 2Y-267.84%
EPS Next 3Y-104.33%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y334.33%
Revenue growth 5Y247.24%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.5%
EBIT growth 1Y93.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-238.83%
EBIT Next 3Y-65.01%
EBIT Next 5YN/A
FCF growth 1Y86.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.83%
OCF growth 3YN/A
OCF growth 5YN/A

NEUPHORIA THERAPEUTICS INC / NEUP Fundamental Analysis FAQ

What is the fundamental rating for NEUP stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEUP.


What is the valuation status of NEUPHORIA THERAPEUTICS INC (NEUP) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUPHORIA THERAPEUTICS INC (NEUP). This can be considered as Overvalued.


Can you provide the profitability details for NEUPHORIA THERAPEUTICS INC?

NEUPHORIA THERAPEUTICS INC (NEUP) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for NEUP stock?

The Earnings per Share (EPS) of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to decline by -1180.52% in the next year.